New Options for the Treatment of Obesity and Type 2 Diabetes Mellitus (Narrative Review)

J Diabetes Complications. Sep-Oct 2013;27(5):508-18. doi: 10.1016/j.jdiacomp.2013.04.011. Epub 2013 May 28.

Abstract

Moderate weight loss (>5%), which has been associated with improvements in glycemic parameters in patients with dysglycemia, also reduces the presence of other comorbidities, including dyslipidemia and hypertension, culminating in a reduced risk of cardiovascular disease. Lifestyle changes are the recommended preliminary approach to weight loss, with an initial weight-loss goal of 10% of body weight achieved over 6 months at a rate of 1-2 pounds per week selected as an appropriate target to decrease the severity of obesity-related risk factors. Implementing and maintaining the lifestyle changes associated with weight loss can, however, be challenging for many patients. Therefore, additional interventions sometimes may be necessary. Bariatric surgery can also be a highly effective option for weight loss and comorbidity reduction, but surgery carries considerable risks and is still applicable only to selected patients with type 2 diabetes. Thus, attention is turning to the use of weight-loss medications, including 2 recently approved compounds: twice-daily lorcaserin and a once-daily combination of phentermine and topiramate extended-release, both shown to be safe and effective therapies in the management of obesity in patients with type 2 diabetes.

Keywords: Cardiovascular; Obesity; Phentermine; Topiramate extended-release; Type 2 diabetes.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Anti-Obesity Agents / pharmacology
  • Anti-Obesity Agents / therapeutic use
  • Bariatric Surgery
  • Diabetes Mellitus, Type 2 / complications
  • Diabetes Mellitus, Type 2 / therapy*
  • Drugs, Investigational / therapeutic use
  • Humans
  • Obesity / complications
  • Obesity / therapy*
  • Risk Reduction Behavior

Substances

  • Anti-Obesity Agents
  • Drugs, Investigational